Middle East Liquid Embolic Agent Market (2025 - 2033)

Middle East Liquid Embolic Agent Market Summary

The Middle East liquid embolic agent market size was estimated at USD 8.08 million in 2024 and is projected to reach USD 10.92 million by 2033, growing at a CAGR of 3.13% from 2025 to 2033. The Middle East liquid embolic agent market is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases.

As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions such as aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The rise in prevalence of neurovascular and oncological disorders such as stroke, brain aneurysms, and cancers, many of which require embolization therapies. As the population ages and lifestyle-related diseases become more common, demand for effective, targeted treatments to manage complex vascular issues is growing. Liquid embolic agents are particularly effective in such scenarios, increasing their usage in neurovascular and oncological procedures. According to an article published in Galadari Printing and Publishing LLC and the Sheikh Khalifa Stroke Institute (SKSI), doctors are raising concerns over the rising number of younger stroke patients in the UAE, with an estimated 9,000 to 12,000 residents suffering a stroke each year. Alarmingly, around half of these cases occur in individuals under the age of 45-approximately 20 years younger than the global average age of 65.

“Stoke, however, is preventable. Individuals who get strokes usually suffer with sudden onset of limb weakness, speech difficulty, or difficulty in finding words, and an inability to use their hand or legs. If the patient arrives at the hospital or stroke center within the window period of four and half hours, the clot can be dissolved using medicines, commonly known as clot busters,” Dr Sandeep Burathoki, consultant interventional radiologist at International Modern Hospital Dubai, told Khaleej Times.

As liquid embolic agents are also used in minimally invasive cancer treatment to block blood flow to tumors for its growth inhibition, the growing cancer cases is also expected to fuel market growth over the forecast period. For instance, the graph below shows cancer mortality for both sexes, including non-melanoma skin cancer, in select Gulf countries as of 2022. Among these, Saudi Arabia reported the highest number of cancer-related deaths at 13,399, reflecting its larger population and increasing burden of non-communicable diseases.

Increasing investment in healthcare is a key driver of the Middle East liquid embolic agent market, particularly for advanced treatment areas such as interventional radiology and liquid embolic agents. Governments across the region, especially in Gulf countries such as Saudi Arabia, the UAE, and Kuwait, are significantly expanding healthcare budgets to modernize infrastructure, improve patient outcomes, and reduce reliance on overseas treatment. These investments fuel the construction of new hospitals, upgrading specialized departments, and procuring advanced medical technologies. As a result, there is a growing demand for minimally invasive therapies that are safer, faster, and more cost-effective-such as those involving liquid embolic agents for treating conditions such as arteriovenous malformations and cerebral aneurysms. Moreover, healthcare privatization and public-private partnerships are opening the market to international medical device manufacturers, further accelerating access to innovative embolization products. This trend is enhancing local health systems' capacity and positioning the Middle East as an emerging hub for high-end medical care in the broader region. According to the International Trade Administration, as of September 2024, the Kuwaiti government allocated USD 10 billion to its healthcare sector for the 2024/2025 budget, representing 11% of the total national budget. Of this amount, USD 608 million is dedicated to healthcare infrastructure, including plans to build and expand 10 hospitals over the next five years, while USD 56 million is allocated to support digital transformation initiatives within the sector.

Market Concentration & Characteristics

The Middle East liquid embolic agent market exhibits a moderate to high degree of innovation, driven by advancements in minimally invasive oncology treatments and growing healthcare infrastructure. Innovations include the development of more biocompatible and radiopaque embolic materials, improved delivery systems for precise targeting, and the integration of imaging technologies to enhance treatment efficacy.

Regulatory frameworks in the Middle East significantly impact the Middle East liquid embolic agent market by ensuring safety and efficacy standards for these advanced medical devices. While stricter regulations can delay product approvals and market entry, they also build trust among healthcare providers and patients. Variations in regulatory processes across countries sometimes create challenges for uniform market access. Efforts to streamline and harmonize regulations are underway, which is expected to facilitate faster adoption and innovation in the region. Balanced regulation is key to supporting market growth while maintaining patient safety.

In the Middle East, the liquid embolic agent market faces competition from alternative embolization products such as coil embolization devices, vascular plugs, and solid embolic materials such as particles and sclerosants. These substitutes are often preferred for their cost-effectiveness, simpler handling, and proven effectiveness in specific procedures. In addition, the availability and familiarity of these alternatives among healthcare providers influence their widespread use. As a result, liquid embolic agents must continuously demonstrate superior safety, precision, and versatility to maintain and grow their market share in the region.

The Middle East liquid embolic agent market is expanding as countries like the UAE and Saudi Arabia invest in healthcare infrastructure and raise awareness of minimally invasive treatments. Emerging markets such as Kuwait and Oman are also adopting these technologies. Government initiatives and rising neurovascular and oncology cases drive demand, while partnerships between global companies and local distributors help broaden market access across the region.

Product Type Insights

The Ethylene Vinyl Alcohol Copolymer (EVOH) segment dominated the Middle East liquid embolic agent market in 2024, with growing adoption across the Middle East. While publicly documented clinical cases in the region remain limited, agents such as Onyx (Medtronic) and Histocryl (B.Braun SE) are increasingly utilized in advanced healthcare facilities in countries such as the UAE, Saudi Arabia, and Qatar. Their proven effectiveness in managing complex vascular conditions such as arteriovenous malformations (AVMs), hypervascular tumors, and visceral hemorrhages aligns with the region’s rapid expansion in interventional radiology and neurovascular care. With the availability of these agents and continued investment in specialized medical infrastructure, EVOH usage in the Middle East is expected to rise significantly.

Application Insights

The Arteriovenous Malformations (AVM) segment dominated in the Middle East Liquid Embolic agent market in 2024. This dominance is driven by the increasing prevalence of AVMs, improved diagnostic capabilities, and the growing adoption of minimally invasive treatment options across the region. EVOH-based embolic agents, particularly non-adhesive formulations such as Onyx, are widely used in AVM management because they enable precise, controlled embolization with minimal complications. In advanced care centers across the UAE, Saudi Arabia, and Qatar, these agents are preferred for complex neurovascular interventions, often performed with surgical or radio surgical procedures. Beyond AVMs, liquid embolic agents are also gaining traction in treating hyper vascular tumors, aneurysms, and visceral artery bleeding, reflecting the region’s broader shift toward image-guided, catheter-based therapies in neurovascular and peripheral vascular applications.

For instance, on 16 February 2024, a clinical advisory board in Saudi Arabia reviewed national hepatocellular carcinoma (HCC) data, revealing significant gaps in managing intermediate to advanced-stage cases. Experts highlighted that most HCC patients are diagnosed at later stages with limited treatment options. Given this challenge, liquid embolic agents, particularly used in trans arterial chemoembolization (TACE), have become increasingly relevant in the country. The panel emphasized the need for broader access to embolic therapies, improved surveillance protocols, and a multidisciplinary approach to enhance outcomes in unresectable HCC cases across Saudi Arabia.

End Use Insights

The hospitals segment dominated the Middle East liquid embolic agent market in 2024. This dominance is driven by the concentration of complex endovascular procedures such as treating arteriovenous malformations (AVMs), hyper vascular tumors, and peripheral hemorrhages within hospital settings across the region. Tertiary care hospitals in countries such as the UAE, Saudi Arabia, and Qatar are increasingly equipped with advanced imaging technologies and staffed by specialized interventional radiologists, making them well-suited for delivering liquid embolic therapies. The growing investment in healthcare infrastructure and the expansion of neurovascular and oncology services further reinforce the central role of hospitals in adopting and applying these agents in the Middle East.

The ambulatory surgery centers (ASCs) segment is expected to register the fastest CAGR in the Middle East during the forecast period, driven by the region's growing shift toward minimally invasive procedures. ASCs in countries such as the UAE and Saudi Arabia are increasingly equipped to handle image-guided interventions, making them well-suited for embolization procedures using liquid embolic agents. These treatments offer shorter recovery times and reduce procedural risk, aligning with patient preferences for outpatient care. In addition, the cost-effectiveness of ASCs compared to hospital settings is appealing to both healthcare providers and patients, further supporting the expansion of embolization services in these facilities across the Middle East.

Country Insights

Saudi Arabia Liquid Embolic Agent Market Trends

Saudi Arabia accounted for the largest revenue share of 20.45% in Middle East liquid embolic agent market in 2024, driven by increasing use in neurovascular interventions, oncology, and trauma-related procedures. Significant investments in healthcare infrastructure and expanding interventional radiology departments in leading hospitals support this trend. However, challenges such as high procedure costs, limited insurance coverage, and the need for more trained specialists may slow broader adoption.

Saudi Arabia is steadily increasing the use of agents such as Onyx, particularly for treating arteriovenous malformations and hyper vascular tumors in top-tier medical centers. For example, in January 2023, a national consensus was developed in Saudi Arabia to guide the prevention and management of cancer-associated thrombosis (CT), recognizing the country’s high burden due to inherited thrombophilia. Experts recommended risk-based use of low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) for medical oncology patients, along with universal prophylaxis for those undergoing cancer-related surgery. This guidance is particularly relevant to the use of liquid embolic agents, as both CT management and embolization procedures often overlap in oncology care. Coordinated planning is essential to balance the risks of bleeding and thrombosis, especially during vascular interventions in patients with hyper vascular tumors.

UAE Liquid Embolic Agent Market Trends

The UAE liquid embolic agent market is expected to witness a significant growth in the Middle East, driven by rapid advancements in healthcare infrastructure, increased demand for minimally invasive procedures, and expanding interventional radiology capabilities. Hospitals across the country are increasingly adopting liquid embolic agents such as Onyx to treat conditions such as arteriovenous malformations (AVMs), hyper vascular tumors, and acute bleeding. This growth is further supported by substantial government investment in specialized care and a push toward modernizing neurovascular and oncologic treatment protocols. While high costs and limited reimbursement pose challenges, the UAE's commitment to cutting-edge medical technologies positions it as a regional leader in embolization therapies.

Kuwait Liquid Embolic Agent Market Trends

The Kuwait liquid embolic agent market is gradually expanding, driven by a growing demand for minimally invasive neurovascular and oncologic care treatments. An aging population, which is more susceptible to conditions such as arteriovenous malformations, aneurysms, and cancer-related bleeding, is a key factor contributing to this rise. Hospitals are increasingly adopting advanced embolization techniques using agents such as Onyx and Squid to manage such cases effectively. This growth is further supported by investments in interventional radiology and the continuous modernization of healthcare infrastructure. While still developing compared to larger Gulf countries, Kuwait holds strong potential for broader adoption of liquid embolic therapies during the forecast period.

Oman Liquid Embolic Agent Market Trends

The liquid embolic agent market in Oman is supported by the country’s growing focus on minimally invasive procedures and improvements in healthcare infrastructure. Rising cases of neurovascular disorders, hyper vascular tumors, and trauma-related bleeding are driving demand for advanced embolization therapies. In addition, the increasing prevalence of non-communicable diseases, an aging population, and greater awareness among healthcare professionals contribute to market growth. While still in the early stages compared to neighboring Gulf countries, Oman is steadily advancing in adopting liquid embolic agents, particularly in tertiary care hospitals with expanding interventional radiology capabilities.

Qatar Liquid Embolic Agent Market Trends

The Qatar liquid embolic agent market growth is propelled by increasing investments in interventional radiology infrastructure and a rising need for minimally invasive vascular treatments. The aging population and a growing incidence of neurovascular and oncology-related conditions drive demand for advanced embolization therapies such as those involving liquid embolic agents. Hospitals in Doha and other urban centers are gradually expanding their adoption of agents such as Onyx and Squid to manage cases of arteriovenous malformations, hyper vascular tumors, and trauma-related hemorrhage. While still in development compared to larger GCC markets, Qatar’s healthcare modernization and emphasis on precision medicine position it well for accelerated uptake of these technologies in the near term.

Key Middle East Liquid Embolic Agent Company Insights

Medtronic, B. Braun SE, Terumo, Gem srl, and Meril are some of the major players in the Middle East liquid embolic agent market. Companies in the industry are introducing products and expanding their manufacturing capacities to strengthen their market presence. In addition, manufacturers are investing significantly in development of liquid embolic agent to enhance global distribution and meet growing international demand.

Recent Developments

• In July 2025, Medtronic announced the enrollment of the first patient in the PEripheral Onyx Liquid Embolic (PELE) clinical trial. This study aims to assess the safety and efficacy of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhages in the peripheral vasculature.

• In July 2024, Arsenal Medical announced that the EMBO-01 clinical trial, an open-label, multicenter, prospective study of NeoCast, successfully met its primary feasibility and safety goals. The study demonstrated that NeoCast achieved predictable and well-controlled vascular occlusion, showcasing its effectiveness as a shear-responsive liquid embolic material engineered for deep distal penetration into the microvasculature.

• In March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS’s hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. Designed to streamline procedure preparation, the set simplifies the process by consolidating essential components into a single sterilized package.

Middle East Liquid Embolic Agent Market